Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Investor Presentation (March 2018)
19 slides from Aurobindo Pharma's investor presentation, March 2018
Slide 1: Leading Vertically Integrated Generic Player
LEADING VERTICALLY INTEGRATED GENERIC PLAYER March 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma, nor shall it, or any
Slide 3: Aurobindo Pharma at a Glance
Aurobindo Pharma at a Glance 12th 3rd 5th Largest listed Indian Largest generic company by Largest generic company by Pharmaceutical company by sales globally# volume in the US** revenues* Amongst Top 10 Gx companies in 4 out of $ 2.3 Bn 150+ Global Revenues in FY17 Top 5 Europe Countries@ Markets P
Slide 4: Key Accomplishments in the Last Year
Key Accomplishments in the Last Year Increasing the complexity and diversity of the portfolio, while retaining the base; augmenting capability and capacity Diversified the drug product & API pipelines: Addressing Rx, Bx, and Consumer Healthcare (OTC and Dietary Supplements) segments Covering k
Slide 5: Emerged into a leading global generic player
Emerged into a leading global generic player 2007* 2017 Revenue $ 317 Mn $ 2.3 Bn EBITDA margin (%) 14.2% 22.8% Formulations 31% 80% contribution US Formulations 7% 45% contribution EU Formulations 6% 22% contribution Note: Data related to FY2007 and FY2017. Fx rate: $1 = Rs. 66.9685; * As per IGAAP
Slide 6: The Journey So Far…
The Journey So Far… 2014 Acquired Western European commercial operations from Actavis Acquired Natrol (Consumer 2006-08 Healthcare) Acquired UK based Milpharm 2015-16 Acquired formulations facility, Established OTC presence AuroLife, in US Entered into Biosimilars and 2009-12 Vaccines
Slide 7: Core Strengths
Core Strengths Scale, Diversity & Operational Patient Leadership Strengths Focus • Among Top 3 in >60% of • Large manufacturing • Unwavering commitment to commercial portfolio in facilities inspected and bring access to high- US(1) in terms of approved by US FDA, quality, low-cost generics to prescr
Slide 8: Diversified Revenue Base & Strong Organic growth
Diversified Revenue Base & Strong Organic growth APIs, 20% US, 45% US, 30% APIs, 43% Revenue ARV, 8% Revenue ~$ 1.1 billion ~$ 2.3 billion Growth Markets *, EU, 8% 5% Growth ARV, 12% EU, 22% Markets*, 7% FY13** FY17 *major markets include Brazil, Canada and South Africa Revenue 2,500 Overall growth
Slide 9: US Business Overview
US Business Overview Revenue Subsidiaries Presence 1,200 33% CAGR in FY13 – FY17 1,019 Aurobindo Pharma 1,000 930 Oral Rx 885 USA 792 800 $ Mn 564 600 AuroMedics Injectables 400 323 200 AuroHealth Pharma OTC 0 FY13* FY14* FY15* FY16 FY17 9MFY18 Natrol Dietary Supplements FY13* Revenue Mix FY17 Injec
Slide 10: US Business – Segment Wise Highlights
US Business – Segment Wise Highlights Orals – Aurobindo Pharma USA Injectables - AuroMedics • 73% of overall US business in FY17 • 15% of overall US business in FY17 • 16% y-o-y growth in TRx* • 4th largest Gx injectable company by volume* (1) • 242 approved ANDAs, 35 TAs, and 72 under • 55 approved
Slide 11: EU Business Overview
EU Business Overview India’s Leading Gx company with strong footprint in Europe Operations in 9 countries with full fledged Pharmacy, Hospital and Tender sales infrastructure with commercialized 450+ INNs Ranks amongst the Top 10 Gx companies in four out of Top-5 EU countries. France & Germany
Slide 12: EU: Portfolio Mix Across Channels
EU: Portfolio Mix Across Channels Sales split by Channel Sales split by Therapeutic Profile Sales split by Dosage Forms Powder Gel 2% 1% Dermatology Others Cream 5% 10% Liquid CVS & 1% Antineo Respiratory 13% plastic 27% Injectables 7% & Others 10% Tablet Capsule Digestive 15% 58% Anti- CNS 15% infe
Slide 13: ARV & Growth Markets Business Overview
ARV & Growth Markets Business Overview ARV Business Revenue 6% CAGR in FY13 – FY17 Comprehensive portfolio of 32 products with a robust 200 185 177 pipeline for the future 158 150 138 139 Dolutegravir based regimens are expected to attain ~59% 107 $ Mn 100 market share by 2021 as per CHAI** repo
Slide 14: The Base Business: API
The Base Business : API API capacity is strategic in-terms of vertical integration and supply to regulated markets; Additional investments are made for capacity creation and capability building API business continue to focus on complex products with varying volumes Focus on continuous improvem
Slide 15: Financial Performance
Financial Performance Revenue from Operations ($ Mn) EBITDA & PAT Margin (%) EPS (INR/Share) 24.0 2,253 22.8 22.8 39.3 2,137 21.2 34.7 32.3 1,986 27.0 1,932 15.3 15.2 14.5 13.0 FY15 FY16 FY17 9MFY18 FY15 FY16 FY17 9MFY18 FY15 FY16 FY17 9MFY18 EBITDA Margin PAT Margin Gross Block & Fixed Asset Turnov
Slide 16: Shifting Paradigms ...
Shifting Paradigms ... Past Present Future Full spectrum of APIs, including peptides and special-polymers Specialty Products: Complex dosage forms and delivery platforms Difficult-to-make and non- Biologics, Vaccines small molecule APIs, Branded Rx and OTC products Complex Oral, and simple Core stre
Slide 17: Focus on Building a Diverse and Robust Specialty Products Portfolio
Focus on Building a Diverse and Robust Specialty Products Portfolio Short Term - 2018 - Strengthen & Diversify Portfolio biosimilars, oncology, peptides, respiratory, Controlled Substances topicals, vaccines etc with ADF - R&D and Manufacturing capability & capacity in India Complex and US Oral Soli
Slide 18: Enhanced Research & Development Capabilities
Enhanced Research & Development Capabilities 5 R&D centers in Hyderabad, India >1500 scientists and analysts R&D Spend – $ Mn (as % of revenue) 4.7%* 4.3%* Focused on difficult to develop APIs, peptides, etc. 4.0%* 75 Develop modern process technologies like enzyme chemistry 81 3.6%* Dosage Fo
Slide 19: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725401 +91 98486 67906 Email: [email protected] Corporate Office: Water Mark Building, Level-6, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Registered Of
Aurobindo Pharma — Investor Presentation (March 2018) on 6ix